Sphingomyelins

Metabolite of the month – Sphingomyelins

by | Dec 14, 2021 | Blog, Cardiometabolic disease, Metabolite of the month, Neurology

 

History and Evolution

1884: first isolated (Ramstedt et al. 2002) | 1927: structure first identified

Sphingomyelins (SMs) are a type of complex sphingolipid, which are building blocks of eukaryotic cell membranes (Maceyka et al. 2014).

Sphingolipids, discovered in the 1870s by German scientist Johann Thudicum, derive their name from the Egyptian sphinx, because of their mysterious nature (Olson et al 2016). Thudicum first isolated sphingomyelins (SM) in brain tissue in the 1880s (Ramstedt et al. 2002). Their structure was later identified as N-acyl-sphingosine-1-phosphorylcholine.

Beyond contributing to the structure and properties of membranes, SMs are precursors to several lipid second messengers, and play an important role in cell signaling, growth and survival (Maceyka et al. 2014).

Structure and nomenclature

SMs make up the majority of sphingophospholipids (SPH) in mammals, accounting for 2% to 15% of total organ phospholipids (Casares et al. 2019). They are formed from a ceramide and a phosphocholine head group. This means that unlike triglycerides or other phospholipids, SMs do not contain a glycerol backbone: they have a long chain sphingosine backbone, a fatty acid and a phosphocholine head group (Berg  et al. 2002).

The overall shape of lipids dictates membrane fluidity. SMs are shaped like a cylinder, with a hydrophilic head and hydrophobic tails. The first five carbon atoms on the sphingoid base are known as the ‘sphingoid motif’, present in all sphingolipids (Dingjan et al. 2021). This determines how the molecule interacts with other lipids.

As with triglycerides, scientific nomenclature for SMs varies, with the name usually based on the name of the sphingoid base and the fatty acid. At biocrates, we use a nomenclature where the name of the SM corresponds to the entire sphingosine backbone, denoting the number of carbons and double bonds in the fatty acid. For example, SM C18:0 indicates a fatty chain with 18 carbon atoms and no double bonds. We also include a reference to hydroxylation where relevant, such as SM (OH) C22:1.

In SMs, the fatty acyl chains are usually long and saturated or monounsaturated (Chiu et al. 2003). The properties of the fatty acid affect membrane structure. For example, chains with more carbon atoms tend to have higher melting points, which affects membrane fluidity. Around 60% of the fatty acids in the sphingomyelin of neural cells is stearic acid, with 18 carbon atoms (Cipolla 2009). Palmitic acid, with 16 carbon atoms, is more common in peripheral cells (Kikas et al. 2018).

Biosynthesis vs. dietary uptake

De novo synthesis of SM follows a series of enzymatic reactions in the gut, all taking place at the surface of the endoplasmic reticulum. Serine and palmitoyl-CoA combine to produce a ceramide precursor with an additional fatty acyl group. The ceramide is then transported to the Golgi and converted to SM by SM synthase. A diacylglycerol (DAG) is produced as a by-product.

Experiments have shown that dietary supplementation with high levels of sphingolipids could increase circulating SMs, though diet is not the main source of SMs. Because sphingolipids are found in mammal cells, they’re particularly prevalent in diets containing meat, eggs and dairy. Western diets are estimated to contain 200–400mg per day of sphingolipids, with the majority being SM (Norris et al. 2017). During digestion, gut enzymes break down the SM into ceramide and phosphorylcholine. The ceramide may be further converted to produce sphingosine, which can be absorbed by cells and enter the sphingosine-1-phosphate (S1P) pathway (Norris et al. 2017). Animal studies have shown that dietary SM is important for newborn gut development (Norris et al. 2017).

Most dietary SMs are degraded in the gut by glucoceramidases, sphingomyelinases, and ceramidases, and around a quarter are secreted in feces in the form of ceramide.

Sphingomyelin metabolism and cell signaling

SMs are precursors of several active sphingolipids, namely ceramides, sphingosine, and sphingosine-1-phosphate (S1P). These analytes each play different roles in cell signaling, relating to the study of blood vessel formation, inflammation, immune responses, diabetes, ageing, cancer, and degenerative diseases (Hannun et al. 2008).

For example, ceramides mediate cell signaling pathways that affect (and often inhibit) cell growth and survival (Ruvolo P, 2001). High fat diets have been shown to cause an accumulation of ceramides, leading to apoptosis, insulin resistance, inflammation and metabolic disease (Norris et al. 2017).

S1P plays a role in inflammatory pathway signaling and acts on G protein-coupled receptors that influence cell growth, motility and cell proliferation (Hannun et al. 2008). S1P is also known to influence other intracellular targets, for example, by inhibiting histone deacetylases (HDACs), activating TNF-receptor associated factor 2 (TRAF2), and activating beta-secretase 1 (BACE1), among others. This makes it a relevant focus for research into cancer, Alzheimer’s disease, diabetes and osteoporosis (Maceyka et al. 2012).

Sex differences in sphingomyelin levels

Several metabolomic investigations into sex-based differences in the human blood metabolome have focused on SMs. In humans, SMs are commonly found in higher amounts in the blood of females compared to males.

A 2011 study found that concentrations of SMs were significantly lower in men than women (Mittelstrass et al. 2011). SMs and ceramides were found to play a role in a range of chronic disease processes, including atherosclerosis, coronary heart disease and type 2 diabetes. Like other sex differences in metabolism, this suggests that SM concentrations could contribute to the difference in susceptibility between the two sexes for many chronic diseases.

A more recent study of 1212 individuals investigated sex differences in SMs by age. This showed that sphingolipids tended to increase in women and decrease in men with age (Darst et al. 2019). Of 40 sphingolipids tested, 35 were found in higher amounts in women than in men. Aging also appeared to influence a wider range of analytes in women than in men. Post-menopausal women had higher levels of SMs. Interestingly, women with high levels of SMs appear to have a lower risk of AD, while men with high levels of SM have a higher risk of AD, which is not yet fully understood.

Sphingomyelins and neurology

SMs are important components of the myelin sheath which surrounds nerve cell axons, which makes them particularly interesting in the exploration of diseases related to the central nervous system and brain physiopathology (Signorelli et al. 2021).

For example, myelin breakdown is a core feature of Parkinson’s disease (PD) pathology (Signorelli et al. 2021). Various metabolomic studies have sought to gather insights into the signaling mechanisms of SMs in PD. Reducing acid sphingomyelinase has been shown to cause an accumulation of SMs, which is toxic to cells, eventually leading to loss of neuronal plasticity and neurogenesis. A study of mouse embryonic stem cells showed that an accumulation of SM impaired neural differentiation, suggesting that simulating stem cell differentiation through the SM pathway may be a way to inhibit PD progression (Fan et al. 2021).

SMs are also relevant to our understanding of major depressive disorder (MDD). Recent studies have shown that concentrations of sphingolipids in the hippocampus, particularly ceramides, can influence the effect of anti-depressants (Gulbins et al. 2015). Depression can occur when negative stimuli in the hippocampus outweigh positive stimuli. Inhibiting the activity of acid sphingomyelinase with anti-depressants has been found to reduce ceramide load, and therefore reduce negative stimuli.

Ceramides and S1P have been shown to regulate brain cell survival and participate in the pathogenesis of multiple sclerosis (MS). This autoimmune disease causes degradation of the myelin sheath in cells in the brain and spinal cord. Studies have shown that activating the neutral sphingomyelinase–ceramide pathway via oxidative stress mechanisms could lead to the death of oligodendrocytes, which influence MS symptoms. Similarly, inhibiting antagonists of S1P receptors involved in autoimmune processes could limit neuroinflammation and demyelination in MS (Jana et al. 2010).

Sphingolipids and cardiometabolic diseases

Accumulation of sphingolipids has been demonstrated in humans and animals with obesity, which is associated with many metabolic diseases (Holland et al. 2008). Sphingolipids have been shown to influence cellular activity leading to insulin resistance, pancreatic disease, cardiomyopathy, and vascular disease. More recently, inhibition of enzymatic sphingolipid synthesis has been shown to limit insulin resistance, diabetes, and atherosclerosis (Holland et al. 2008).

Animal studies have also shown that dietary sphingolipids affect cholesterol absorption, which is of interest in the study of inflammatory bowel disease and colon cancer. Dietary SM has been shown to exert chemo preventive and chemotherapeutic effects in rodent with colon cancer (Yamashita et al. 2021).

Sphingomyelin has been identified in human studies as an independent risk factor for atherosclerosis (Yu et al. 2019). However, the mechanisms are not well understood, and other studies have found long chain saturated sphingomyelins to have a protective effect on cardiovascular health (Sigruener et al. 2014).

 


References

Berg J. et al.: There Are Three Common Types of Membrane Lipids. (2002) Biochemistry |  https://www.ncbi.nlm.nih.gov/books/NBK22361/

Casares D. et al.: Membrane Lipid Composition: Effect on Membrane and Organelle Structure, Function and Compartmentalization and Therapeutic Avenues. (2019) International Journal of Molecular Sciences | https://doi.org/10.3390/ijms20092167

Chiu S. et al.: Structure of Sphingomyelin Bilayers: A Simulation Study. (2003) Biophysical Journal | https://doi.org/10.1016/S0006-3495(03)74780-8

Cipolla L.: Chemistry of Natural Compounds. (2009) Organic and Bio-Molecular Chemistry – Vol 1. (p. 280)

Darst B. et al.: Longitudinal plasma metabolomics of aging and sex. (2019) Aging | https://doi.org/10.18632/aging.101837

Dingjan T. & Futerman H.: The role of the ‘sphingoid motif’ in shaping the molecular interactions of sphingolipids in biomembranes. (2021) Biochimica et Biophysica Acta (BBA) – Biomembranes | https://doi.org/ 10.1016/j.bbamem.2021.183701

Fan W. et al.: SIRT1 regulates sphingolipid metabolism and neural differentiation of mouse embryonic stem cells through c-Myc-SMPDL3B. (2021) eLife | https://doi.org/10.7554/eLife.67452

Gulbins E. et al.: A central role for the acid sphingomyelinase/ceramide system in neurogenesis and major depression. (2015) Journal of Neurochemistry | https://doi.org/10.1111/jnc.13145

Hannun Y. & Obeid L.: Principles of bioactive lipid signalling: lessons from sphingolipids. (2008) Nature Reviews Molecular Cell Biology | https://doi.org/10.1038/nrm2329

Holland W. & Summers S.: Sphingolipids, Insulin Resistance, and Metabolic Disease: New Insights from in Vivo Manipulation of Sphingolipid Metabolism. (2008) Endocrine Reviews | https://doi.org/10.1210/er.2007-0025

Jana A. & Pahan K.: Sphingolipids in Multiple Sclerosis. (2010) Neuromolecular Medicine | https://doi.org/10.1007/s12017-010-8128-4

Kikas P. et al.: Cardiovascular Implications of Sphingomyelin Presence in Biological Membranes. (2018) European Cardiology Review | https://doi.org/10.15420/ecr.2017:20:3

Maceyka M. et al.: Sphingosine-1-phosphate signaling and its role in disease. (2012) Trends Cell Biol., | https://doi.org/10.1016/j.tcb.2011.09.003

Maceyka M. & Spiegel S.: Sphingolipid metabolites in inflammatory disease. (2014) Nature | https://doi.org/10.1038/nature13475

Mittelstrass K. et al.: Discovery of Sexual Dimorphisms in Metabolic and Genetic Biomarkers. (2011) PLoS Genetics | https://doi.org/10.1371/journal.pgen.1002215

Nilsson Å.: The presence of sphingomyelin- and ceramide-cleaving enzymes in the small intestinal tract. (1969) Biochimica et Biophysica Acta (BBA) – Lipids and Lipid Metabolism | https://doi.org/10.1016/0005-2760(69)90192-1

Norris G. & Blesso C.: (2017) Dietary and Endogenous Sphingolipid Metabolism in Chronic Inflammation. (2017) Nutrients | https://doi.org/10.3390/nu9111180

Olson D. et al.: Taming the Sphinx: Mechanisms of Cellular Sphingolipid Homeostasis. (2016) Biochim Biophys Acta | https://doi.org/10.1016/j.bbalip.2015.12.021

Ramstedt B. & Slotte JP.: Membrane properties of sphingomyelins. (2002) FEBS Letters | https://doi.org/10.1016/S0014-5793(02)03406-3

Ruvolo P.: Ceramide regulates cellular homeostasis via diverse stress signaling pathways. (2001) Leukemia, | https://doi.org/10.1038/sj.leu.2402197

Signorelli P. et al.: The Multiple Roles of Sphingomyelin in Parkinson’s Disease. (2021) Biomolecules | https://doi.org/10.3390/ biom11091311

Sigruener A. et al.: Glycerophospholipid and Sphingolipid Species and Mortality: The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. (2014) PLoS One | https://doi.org/10.1371/journal.pone.0085724

Yamashita S. et al.: Dietary Sphingolipids Contribute to Health via Intestinal Maintenance. (2021) International Journal of Molecular Sciences | https://doi.org/10.3390/ijms22137052

Yu Z. et al.: Potential therapeutic targets for atherosclerosis in sphingolipid metabolism. (2019) Clinical Science | https://doi.org/10.1042/CS20180911